Drug Interaction Study Between Dorzagliatin and Sitagliptin
Status:
Completed
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of
glucokinase activator dorzagliatin and sitagliptin in subjects with T2DM. Pharmacokinetics
and pharmacodynamics when dorzagliatin and sitagliptin given alone and in combination will be
studied.